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We examined cancer incidence in relation to oral contraceptive (OC) use in the Oxford Family Planning Association contraceptive
study. The study includes 17032 women, recruited at family planning clinics at ages 25–39 years between 1968 and 1974, who were
using OCs, a diaphragm, or an intrauterine device. Follow-up data were available until 2004. OC use was not significantly related to
nonreproductive cancer. Breast cancer findings (844 cases) likewise were very reassuring (rate ratio (RR) comparing women ever
using OCs with those never doing so 1.0, 95% confidence interval (CI) 0.8–1.1). There was a strong positive relationship between
cervical cancer incidence (59 cases) and duration of OC use (RR comparing users for 97þ months with nonusers 6.1, 95%CI,
2.5–17.9). Uterine body cancer (77 cases) and ovarian cancer (106 cases) showed strong negative associations with duration of OC
use: RRs for 97þ months of use were 0.1 (95%CI, 0.0–0.4) and 0.3 (95%CI, 0.1–0.5) respectively. This apparent protective effect
for both cancers persisted more than 20 years after stopping OCs. Combining data for cancers of the cervix, uterine body and ovary,
the age adjusted RR for women ever using OCs compared with those never doing so was 0.7 (95%CI, 0.5–0.8). Beneficial effects of
OCs on the gynaecological cancers thus outweighed adverse effects.
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There has long been concern about oral contraceptive (OC) effects
on cancer, especially breast cancer and the reproductive cancers.
Many epidemiological studies have been reported which have
recently been reviewed by the International Agency for Research
on Cancer (IARC). Only a summary of the findings has been
published to date (Cogliano et al, 2005). It was concluded that (a)
there is a small increase in breast cancer risk in current and recent
combined OC users which has disappeared 10 years after cessation
of use; (b) cervical cancer risk increases with duration of use of
combined OCs; (c) hepatocellular cancer risk is increased in long-
term users of combined OCs in populations with low frequencies
of hepatitis B infection and chronic liver disease; and (d) the risks
of endometrial and ovarian cancer are decreased in users of
combined OCs, the decrease being greater with longer duration of
use. For these cancers, some reduction in risk persists for at least
15 years after cessation of use.
Most epidemiological studies of OCs and cancer have been of
case–control design with all the problems this implies (Jick and
Vessey, 1978). The Oxford-Family Planning Association (Oxford-
FPA) contraceptive study, however, is of cohort design and
commenced in the early years of OC use (1968). Findings in the
study are, therefore, of special importance in assessing the effects
of OCs on cancer risk.
Patterns of cancer incidence in the Oxford-FPA study have been
described previously. Our most recent report on breast cancer
(Vessey et al, 1989) included 189 cases; no evidence was found of
an association between OC use and this disease. A report on
ovarian cancer (42 cases) and endometrial cancer (15 cases) was
published by Vessey and Painter in 1995; an apparent protective
effect of OC use was found for both cancers. Findings on cervical
cancer were presented by Zondervan et al (1996). There were only
33 invasive cases, but the findings strongly suggested that OC
use increased risk. Malignant melanoma (32 cases) has also been
studied; the reassuring results were reported by Hannaford
et al (1991).
We present here our latest findings (to the end of 2004) for these
and other cancers based on much larger numbers of cases than
previously.
MATERIALS AND METHODS
The methods used in the Oxford-FPA study have been described
(Vessey et al, 1976). Briefly, 17032 women were recruited at 17
family planning clinics in England and Scotland from 1968 to 1974.
At entry, each woman was aged 25–39 years, married, white,
British, willing to cooperate and either a current OC user of at least
5 months standing or a current diaphragm or intrauterine device
user of at least 5 months standing without previous OC use. At
recruitment, each woman was asked about her birth date, child-
bearing history, contraceptive history, height, weight, social class
(based on her husbands occupation), smoking habits and medical
history. The records of each woman were flagged in the National
Health Service (NHS) central registries to provide automatic
notification of deaths and cancer registrations.
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I–II and only 10% were from social classes IV–V. In all, 69%
were nonsmokers or ex-smokers; only 14% smoked 15 or more
cigarettes daily. Mean body mass index (weight (kg)/height (m)
2)
was only 22.6. These favourable characteristics reflect the fact
that family planning clinics attract women who are of higher
social class and are more health conscious than the general
population.
Where possible, annual follow-up was based on clinic visits.
Each woman was asked about pregnancies, changes in contra-
ception, cervical cytology and hospital referrals. Where appro-
priate, questions were also asked about hormone replacement
therapy (HRT) and menopausal status. If necessary, women were
sent a postal follow-up form, interviewed by telephone or visited at
home. After 5 years, 32% of women were followed by the clinic,
47% by post, 18% by telephone and 2% by home visit. After 10
years, the corresponding figures were 12, 61, 26 and 1%.
A part-time research assistant worked in each clinic. Yearly
contact was maintained with participants until age 45 with an
annual loss to follow-up for noncooperation or failure to trace
of about 0.4%. Cancer diagnoses were confirmed by obtaining
hospital summaries. All diagnostic coding was carried out
by MV.
At age 45, each woman was allocated to one of three groups: OCs
never used, OCs used for 8 years or more, and OCs used for less
than 8 years. To reduce costs, only those in the first two groups
were subsequently followed-up annually; this continued until mid-
1994. Follow-up of those in the remaining group from reaching age
45 until mid-1994 was limited to cancer registrations and deaths
notified by the NHS central registries. From mid-1994, information
recorded for all the women has been limited to death and cancer
notifications from the registries.
The cancers (or cancer groups) considered in this report are
listed below. For each cancer, the ICD Code (8th Revision) is given
in italics followed by the number of cases. Oesophageal and gastric
cancer (150–151; 42), cancer of colon and rectum (153–154; 131),
lung cancer (162; 115), malignant melanoma of skin (172; 94),
other skin cancer (173; 352), breast cancer (174; 844), cervical
cancer (180; 59), uterine body cancer (182; 77), ovarian cancer
(183.0; 106), bladder and kidney cancer (188–189; 56), lymphomas
and leukaemias (200–208; 130), other cancers of known site
(140–239 less the above; 150), cancers of uncertain site (195–199;
48). None of the uterine cancers was of unknown site while 87%
of the uterine body cancers were endometrial in type. In any given
analysis, women known to have had the relevant cancer before
recruitment were omitted.
The analysis is based on computation of woman-years of
observation. Indirectly standardised incidence rates and rate ratios
were calculated as described by Vessey et al (1976). For
significance tests and calculation of 95% confidence intervals
(CIs) we used methods given by Breslow and Day (1987). We
examined cancer incidence in relation to four categories of total
duration of OC use (never used, 1–48 months, 49–96 months, 97
or more months), and to five categories of interval since last OC
use (never used, 1–48 months, 49–144 months, 145–240 months,
241 or more months). All analyses took age into account (25–34,
35–39, 40–44, 45–49, 50–54, 55–59, 60 or more). The following
variables were also assessed as possible confounders in the OC
analyses for each cancer: parity (0, 1, 2, 3, 4 or more births), social
class at entry (I–II, III, IV–V and other, Registrar General’s
Classification), smoking at entry (never smoked, ex-smoker, 1–14
cigarettes daily, 15 or more cigarettes daily) and body mass index
at entry (up to 19.9, 20–21.9, 22–23.9, 24–25.9, 26–27.9, 28 or
more kg/m
2). We also examined the influence of age at first term
pregnancy (nulliparous, up to 19, 20–24, 25–29, 30 or more) on
breast cancer incidence and of age at first marriage (up to 17, 18–
19, 20–21, 22 or more) on cervical cancer incidence. Variables
having an effect on the age adjusted trend of the cancer concerned
at the 10% or higher level of statistical significance were
considered to be potential confounders.
Data about hysterectomy, oophorectomy, age at menopause and
use of HRT were also judged to be of potential importance.
Information about these variables was collected only while women
were under annual follow-up. Analyses were undertaken within
the relevant part of the database. OC use showed no important
association with hysterectomy, oophorectomy or age at meno-
pause. Among those who had never used OCs, 17% used HRT for
more than 2 years; the corresponding figure for those who had
used OCs for 8 or more years was slightly higher (21%). Viewed
overall, we were reassured that our inability to take any of these
variables into account in the analyses presented here is unlikely to
have distorted the results.
Preparations containing 50mg of oestrogen made up 67% of
OC exposure. The corresponding figure for OCs containing more
oestrogen was 2% and for OCs containing less oestrogen was 18%.
Progestogen-only OCs made up the remainder (13%). As exposure
was dominated by one broad group of OCs and considering the
small numbers of cancers in some categories, the data were not
analysed by OC formulation.
RESULTS
Woman-years of observation
The cancers analysed occurred during 540000 woman-years of
observation. The woman-years were (by chance) distributed more
or less equally between the age groups. The group of nonusers of
OCs included 187000 woman-years (35% of the total) while the
corresponding figure for the group using OCs for 97 months or
more was 116000 (21% of the total). There were 112000 woman-
years (21% of the total) in the group that had used OCs within
the last 48 months while the corresponding figure for the group
who had last used the pill 241 or more months before was 73000
(14% of the total).
Cancer in relation to duration of OC use
The findings are summarised in Table 1 in ICD code order.
Looking first at the nonreproductive cancers, there is no
significant evidence of an association between the risk of any of
these cancers and duration of OC use. Nonetheless, the rate ratios
for lung cancer are all somewhat elevated in OC users; this may
reflect residual confounding, including inadequate adjustment for
smoking which was slightly more common at entry among OC
users than nonusers (Vessey et al, 1976). Within the group of other
cancers of known site, there were three women with hepatocellular
and three with biliary tract cancer. Two of the former and two of
the latter were past OC users; all had used OCs for long periods
(123, 129, 105 and 177 months, respectively).
Breast cancer incidence was unrelated to duration of OC use;
all the rate ratios were close to unity (Table 1). Comparing ever-
users with never-users, the rate ratio was 1.0(0.8–1.1). Cervical
cancer showed a strong positive association with duration of OC
use; the rate ratios increased from 2.9(0.9–9.9) for the up to 48
months group to 6.1(2.5–17.9) for the 97 or more months group.
The ever-used to never-used comparison gave a rate ratio of
4.2(1.8–12.0).
Both uterine body and ovarian cancer were strongly negatively
associated with OC use; the ever-used to never-used comparisons
yielded rate ratios of 0.3(0.2–0.6) and 0.5(0.3–0.7), respectively.
While the rate ratios for uterine body cancer declined steadily
with increasing duration of use, those for ovarian cancer were
below unity only in the last two duration groups, suggesting
that a minimum period of use may be necessary to obtain the
beneficial effect.
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Table 2 shows that there is no significant evidence of an
association between interval since last OC use and any of the
nonreproductive cancers. All four women with liver or biliary duct
tumours who had used OCs had discontinued them more than 144
months previously.
The data for breast cancer are once again completely reassuring.
Approximately half of the cervical cancers are concentrated in the
shortest interval group and this group also has the highest rate
ratio (5.2; 2.1–15.5). In an analysis that separated out the group of
21 cancers occurring in current or recent (within 12 months) OC
users, the rate ratio was 6.8(2.6–20.5). Nonetheless, significantly
increased rate ratios are apparent in the 49–144 months group
(3.9; 1.4–12.3) and the 145–240 months group (4.6; 1.5–15.6)
suggesting that some adverse effect of OCs on cervical cancer may
persist for many years after cessation of use.
By contrast, uterine body and ovarian cancers are concentrated
in the long interval groups (Table 2). Rate ratios are below unity in
every cell for both cancers although there is a trend towards
increasing rate ratios with time elapsed since OCs were stopped for
uterine body cancer which just reaches statistical significance.
Nonetheless, even in the longest interval group the rate ratios for
both cancers are just significantly below unity (0.5, 95% CI 0.3–0.9
and 0.6, 95% CI 0.3–1.0, respectively). These data support the view
that the protective effect of OCs against these two cancers is very
persistent.
DISCUSSION
The data collected in the Oxford-FPA study are known to be
reliable (Vessey, 1998). Nonetheless, the present analyses have
limitations that must be considered before discussing the results.
First, annual follow-up of women who had used OCs for less
than 8 years ceased at age 45. Information about the confounding
variables considered in the present analysis was, however, available
for these women. Furthermore, since pill use was generally
Table 1 Cancer (ICD order) in relation to total duration of OC use
Total duration of oral contraceptive use (months)
Nonuser Up to 48 49 to 96 97 or more All durations
Cancer site No RR No RR No RR No RR No RR
Oesophagus and stomach (1,2,3) 19 1.0 7 0.8 (0.3–1.9) 9 0.7 (0.3–1.7) 7 0.5 (0.2–1.2) 23 0.6 (0.3–1.3)
Rectum and colon (1,4) 56 1.0 26 1.1 (0.6–1.7) 23 0.8 (0.4–1.2) 26 0.8 (0.5–1.2) 75 0.8 (0.6–1.2)
Lung (1,2,3,5) 30 1.0 17 1.2 (0.6–2.3) 30 1.5 (0.8–2.5) 38 1.4 (0.8–2.3) 85 1.4 (0.9–2.1)
Malignant melanoma (1,2,3,6) 40 1.0 9 0.4 (0.2–0.9) 21 0.9 (0.5–1.5) 24 1.0 (0.6–1.7) 54 0.8 (0.5–1.2)
Other skin (1,2,3) 128 1.0 61 1.1 (0.8–1.5) 86 1.2 (0.9–1.6) 77 1.0 (0.7–1.3) 224 1.1 (0.9–1.4)
Breast (1,3,7) 314 1.0 141 0.9 (0.8–1.1) 182 0.9 (0.8–1.1) 207 1.0 (0.8–1.2) 530 1.0 (0.8–1.1)
Uterine cervix (1,2,3,5,8) 6 1.0 9 2.9 (0.9–9.9) 16 3.3 (1.2–10.4) 28 6.1 (2.5–17.9) 53 4.2 (1.8–12.0)
Uterine body (1,4) 50 1.0 12 0.6 (0.3–1.1) 11 0.4 (0.2–0.8) 4 0.1 (0.0–0.4) 27 0.3 (0.2–0.6)
Ovary (1) 58 1.0 28 1.0 (0.6–1.7) 10 0.3 (0.1–0.6) 10 0.3 (0.1–0.5) 48 0.5 (0.3–0.7)
Kidney and bladder (1,4) 24 1.0 6 0.6 (0.2–1.5) 15 1.1 (0.6–2.2) 11 0.7 (0.3–1.5) 32 0.8 (0.5–1.5)
Lymphomas and leukaemias (1) 47 1.0 23 1.1 (0.6–1.8) 28 1.0 (0.6–1.7) 32 1.1 (0.7–1.7) 83 1.1 (0.7–1.6)
Other known (1) 54 1.0 34 1.2 (0.8–1.9) 26 0.8 (0.5–1.3) 36 1.1 (0.7–1.7) 96 1.0 (0.7–1.5)
Uncertain (1,3) 14 1.0 6 1.0 (0.3–2.7) 9 1.1 (0.4–2.6) 19 1.8 (0.9–3.9) 34 1.4 (0.7–2.7)
Numbers within parentheses indicate confounding variables taken into account in each analysis. RR indicates the rate ratio with 95% CI. Nonusers are taken as the reference
group. Confounding variables. 1, age; 2, social class; 3, smoking; 4, body mass index; 5, parity; 6, height; 7, age at first-term pregnancy; 8, age at first marriage. Trend tests. Uterine
cervix, uterine body, ovary: all Po0.001. All other cancers: not significant.
Table 2 Cancer (ICD order) in relation to interval since OCs last used
Interval since last oral contraceptive use (months)
Up to 48 49–144 145–240 241 or more
Cancer site No RR No RR No RR No RR
Oesophagus and stomach 4 0.9 (0.2-2.8) 3 0.5 (0.1-1.6) 8 0.8 (0.3-1.9) 8 0.5 (0.2-1.3)
Rectum and colon 5 0.7 (0.2-1.7) 8 0.6 (0.2-1.3) 25 0.9 (0.6-1.5) 37 0.9 (0.6-1.4)
Lung 2 1.2 (0.1-4.7) 14 1.9 (0.9-3.6) 24 1.2 (0.7-2.1) 45 1.4 (0.8-2.2)
Malignant melanoma 5 0.4 (0.1-0.9) 22 1.4 (0.8-2.4) 11 0.6 (0.3-1.1) 16 0.8 (0.4-1.5)
Other skin 9 0.6 (0.3-1.1) 31 0.9 (0.6-1.3) 75 1.2 (0.9-1.6) 109 1.2 (0.9-1.5)
Breast 79 1.1 (0.8-1.4) 113 0.9 (0.7-1.1) 184 1.1 (0.9-1.3) 154 0.9 (0.7-1.1)
Uterine cervix 26 5.2 (2.1-15.5) 15 3.9 (1.4-12.3) 10 4.6 (1.5-15.6) 2 1.3 (0.1-7.2)
Uterine body 0 — 1 0.1 (0.0-0.5) 8 0.3 (0.1-0.7) 18 0.5 (0.3-0.9)
Ovary 1 0.1 (0.0-0.5) 10 0.5 (0.2-0.9) 14 0.5 (0.2-0.9) 23 0.6 (0.3-1.0)
Kidney and bladder 1 0.3 (0.0-1.9) 8 1.1 (0.4-2.6) 7 0.6 (0.2-1.4) 16 0.9 (0.5-1.8)
Lymphomas and leukaemias 11 1.2 (0.6-2.4) 11 0.8 (0.4-1.6) 28 1.3 (0.8-2.1) 33 1.0 (0.6-1.6)
Other known site 19 1.0 (0.6-1.7) 15 0.8 (0.4-1.5) 28 1.1 (0.7-1.6) 34 1.0 (0.6-1.6)
Uncertain site 2 1.9 (0.2-8.2) 4 1.1 (0.3-3.5) 11 1.4 (0.6-3.3) 17 1.4 (0.6-3.0)
Confounding factors taken into account in each analysis are shown in Table 1. RR indicates the rate ratio with 95% CI. Nonusers are taken as the reference group but data are not
shown here – see Table 1. Trend tests Uterine body: Po0.05. All other cancers: not significant.
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up ceased at that age were still using OCs), accurate information
about OC exposure was also available for this group. Indeed, the
only way in which the information available for the women in
whom annual follow-up stopped at age 45 differed materially from
that available for the other women, concerns cancers occurring
between age 45 and the general cessation of annual follow-up
in mid-1994. For the former group, cancer information in the
relevant interval came only from the NHS central registries. For the
latter group, cancer information also came from the annual follow-
up. It is thus possible that there might be some under-
ascertainment of cancer (especially nonmelanoma skin cancer)
in the analyses concerning women using OCs for up to 8 years in
comparison with the other groups of women. Table 1, however,
provides no indication of such under-ascertainment (even in the
other skin cancer group) and it seems reasonable to conclude that
the study procedures when women reached age 45 have not
significantly biased our findings.
Secondly, annual follow-up ceased generally in mid-1994.
Consequently, information about cancer beyond mid-1994 (to
the present closure date in December 2004) came only from the
registries. This implies some under-ascertainment of the different
cancers (especially for the most recent years and for nonmelanoma
skin cancer). This, however, should not bias the present OC
analyses since under-ascertainment beyond mid-1994 is most
unlikely to have been affected by OC use.
Thirdly, information about hysterectomy, oophorectomy, age at
menopause and HRT use was obtained only while women were
being followed-up annually. We have assumed that the available
findings apply more generally to the analyses presented here. This
assumption is unlikely to have distorted the results. Fourthly, the
numbers of cancers included in many of the comparisons are small
and many rate ratios have wide CI. Finally, our findings relate
mainly to OCs containing 50mg of oestrogen, a high dose by
today’s standards.
The extent to which our findings can be generalised is
important. Women attending family planning clinics are of higher
social class and more health conscious than women in general.
Despite this, we see no reason why our findings should not be
broadly applicable, especially in terms rate ratios (which we have
chosen to present) rather than incidence rates.
In assessing our findings in relation to other work, it must be
stressed that there is a substantial literature on OCs and cancer. In
the interests of space, and to obtain an unbiased interpretation of
the literature, reference is best made to reliable independent
overviews. The IARC produces such overviews as part of their
monograph series. Monograph 72 (IARC, 1999) provides an
overview of work published to mid-1998. An updated volume,
Monograph 91, has recently been completed but has yet to be
published. Nonetheless, the main conclusions of the group are
available (Cogliano et al, 2005) and have been summarised in our
introduction.
Our study is too small to provide useful information about
hepatocellular cancer save to underline its rarity in the United
Kingdom. The negative findings for the other nonreproductive
cancers are in line with the IARC conclusions (Cogliano et al,
2005). We also found no relationship between OC use and breast
cancer, based on substantial numbers of cases (844). Only 192 of
these cases, however, occurred within 144 months of cessation of
OC use and the rate ratios in the intervals up to 48 months and
49–144 months were 1.1(0.8–1.4) and 0.9(0.7–1.1), respectively.
These data do not exclude a small increase in risk (about 20% in
current users declining to no increase 10 years after stopping) as
described by the Collaborative Group on Hormonal Factors in
Breast Cancer (1996) on which the IARC conclusions appear
largely to be based.
Our findings, despite the small number of cases (53), provide
strong evidence for a considerable increase in cervical cancer risk
in OC users. The risk increases with duration of OC use, in line
with the IARC report (Cogliano et al, 2005). We published broadly
similar findings for cervical cancer from the Oxford FPA study 10
years ago (Zondervan et al, 1996). This earlier analysis included 33
women with invasive cancer and 280 with cervical intraepithelial
neoplasia. It was possible to take several factors into account
in that analysis not considered here including use of barrier
contraceptives, male and female sterilisation and abortion history.
In addition, the (very) limited study data on sexual behavioural
factors and the incomplete study information on cytological
screening were discussed. We concluded that none of the factors
considered was likely to explain the association between OC use
and cervical cancer.
Human papilloma virus (HPV) infection in relation to OC use
and cervical cancer is also important. Our study provides no
information on this topic which is, however, considered in detail in
a recent systematic review by Smith et al (2003). In that review, the
summary relative risks for cervical cancer were 1.1 (1.1–1.2) for
less than 5 years OC use, 1.6 (1.4–1.7) for 5–9 years use and 2.2
(1.9–2.4) for 10 or more years use. The figures were similar when
the analysis was limited to HPV positive women. These relative
risks are much lower than our rate ratios suggesting, perhaps, that
some unknown factor is operating in our study to elevate the
apparent risk associated with OC use. Further reliable information
about OCs and cervical cancer is available in a report from the
Collaborative Group on Epidemiological Studies of Cervical Cancer
(submitted for publication). This report shows that the elevated
risk in OC users has disappeared 10 years after cessation of use.
Our findings (Table 2) are at variance with this result: we do not
know why.
Our findings for uterine body cancer are again in line with those
of the IARC (Cogliano et al, 2005). The risk of developing such a
cancer decreased markedly with increasing duration of OC use.
There was only one case among users who had last taken OCs
within the previous 144 months and the results given in Table 2
suggest that some protective effect may continue for more than 20
years after stopping. Our findings fit in well with other published
work although we have found a stronger protective effect than has
been reported in recent reviews (IARC, 1999; Population Reports,
2000; Deligeoroglou et al, 2003).
Our data strongly support the conclusions of the IARC
(Cogliano et al, 2005) and recent reviews in indicating a protective
effect of OCs against ovarian cancer (Population Reports, 2000;
Deligeoroglou et al, 2003; Riman et al, 2004). In our study, there
was no effect with durations of OC use up to 48 months; marked
protection was, however, apparent in the longer duration of use
groups. There was little evidence that the protective effect waned
with the passage of time since OCs were stopped; indeed, a
protective effect was still apparent in women discontinuing OC use
more than 20 years before (Table 2).
Does the beneficial effect of OCs on cancers of the uterine body
and ovary outweigh the harmful effect on cervical cancer? To
investigate this question, we pooled the data for the three cancers
and carried out a simple analysis, adjusting for the effects of age.
The rate ratio comparing women who had ever used OCs with
those who had never done so was 0.7 (95% CI 0.5–0.8). The
adjusted incidence rates per 1000 woman-years were 0.37 (95%
CI 0.31–0.45) and 0.57 (95% CI 0.47–0.69) respectively. In our
study, these data indicate an overall beneficial effect of OC use on
cancer risk.
In summary, our findings on cancer and OC use are clear cut
and largely consistent with reviews of other studies. The results
are of particular importance because they are derived from a
cohort study with reliable data on OC exposure and cancer
incidence and considerable quantities of information about long-
term OC use (more than 8 years) and about OC effects 20 years
and more after OC discontinuation. Furthermore, our study
provides information about the full range of cancers and not just
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course, apply only to the OCs widely used in the 1970s and 1980s;
other studies are required to evaluate the long-term effects of the
preparations used today. Many older women, however, whose use
of OCs ended 20–25 years ago, should be reassured by our
findings.
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